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Historically, androgen-deprivation therapy (ADT) was the only primary treatment for 
metastatic prostate cancer. After prostate cancer develops into castration-resistant 
prostate cancer (CRPC), there are a few life-prolonging drugs, including taxanes, such 
as docetaxel and cabazitaxel, as well as novel androgen receptor-targeting agents, 
such as abiraterone acetate and enzalutamide, which have been proved in clinical trials. 
However, the prognosis of men with CRPC is still poor. The duration from initiation 
of ADT to CRPC has not improved in recent decades because no novel therapeutic 
options have emerged. However, recently, up-front docetaxel chemotherapy has been 
shown to prolong progression-free as well as overall survival in men with metastatic hor-
mone-naïve prostate cancer. This offers a new way to expand the role of chemotherapy 
for hormone-naïve prostate cancer. In this review, we summarize the proof-of-concept 
as well as the current status of taxane chemotherapy for hormone-naïve prostate cancer, 
focusing on phase 3 clinical trials investigating oncological outcome, and discuss the 
future direction in this field.
Keywords: androgen-deprivation therapy, cabazitaxel, castration-resistant prostate cancer, docetaxel, hormone-
naïve prostate cancer
inTRODUCTiOn
Previously, hormonal therapy such as androgen-deprivation therapy (ADT) using surgical or 
pharmacological castration and/or antiandrogens was the only gold standard for therapy of meta-
static prostate cancer. However, historically, the efficacy of ADT was limited, and most prostate 
cancer developed into castration-resistant prostate cancer (CRPC) in about 2 years. When pros-
tate cancer developed into CRPC, until 2004, there were no life-prolonging drugs that had been 
proved by clinical trial, and prognosis of men with CRPC was poor. However, in 2004, docetaxel 
chemotherapy was shown to prolong survival of men with metastatic CRPC (1, 2) and has become 
standard therapy for metastatic CRPC. Since 2010, in addition to the immunotherapeutic agent 
sipuleucel-T and radiopharmaceutical Ra-223, three agents for metastatic CRPC, including novel 
androgen receptor (AR)-targeting agents abiraterone acetate and enzalutamide, as well as novel 
taxane cabazitaxel, have been shown to prolong overall survival (OS) (3). Accordingly, those 
agents have been approved by the relevant authorities in many countries. Thus, the prognosis of 
men with metastatic CRPC was improved by those novel agents. However, the time to CRPC was 
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not improved where policy dictated that only ADT should be 
administered and no additional therapy was considered.
Recently, some important clinical trials investigating the 
role of docetaxel chemotherapy for metastatic hormone-naïve 
prostate cancer have been reported. In this review, we summarize 
the proof-of-concept and the current status of chemotherapy for 
hormone-naïve prostate cancer, focusing on phase 3 clinical trials 
investigating oncological outcome, and discuss the future direc-
tion in this field.
PROOF-OF-COnCePT BY BASiC 
ReSeARCH
Although chemotherapy has been the gold standard for metastatic 
disease in various types of cancer, there was no life-prolonging 
chemotherapy for prostate cancer until 2004. However, since the 
emergence of docetaxel chemotherapy for metastatic CRPC in 
2004 (1, 2), the hypothesis that docetaxel chemotherapy may be 
effective also for hormone-naïve prostate cancer was generated. 
Accordingly, basic research has been conducted to examine the 
proof-of-concept.
In 2005, Eigl et al. compared tumor growth in three groups 
of mice bearing Shionogi and LNCaP xenografts treated with (i) 
initial castration and delayed paclitaxel; (ii) initial paclitaxel and 
delayed castration; or (iii) simultaneous castration plus paclitaxel 
(4). Simultaneous ADT plus paclitaxel was more effective than 
sequential treatment by initial castration and delayed paclitaxel 
in both xenograft models (4), although there was no difference in 
an MDA PCa2b xenograft model (5). In line with this notion, we 
have recently shown cross-resistance to docetaxel in CRPC cells, 
but not vice  versa using an LNCaP cell model (6). Thus, these 
results provide proof-of-concept for possible superior anticancer 
activity of up-front taxane chemotherapy for hormone-naïve 
prostate cancer, compared with traditional ADT followed by 
docetaxel chemotherapy.
Several studies have examined whether metastatic status 
affects the efficacy of taxane chemotherapy. Marín-Aguilera et al. 
reported that gene expression related to epithelial–mesenchymal 
transition was altered in radical prostatectomy specimens when 
treated with neoadjuvant docetaxel chemotherapy, and correlated 
with relapse (7). Also, mesenchymal marker expression was 
upregulated in docetaxel-resistant cells, in which knockdown 
of mesenchymal marker ZEB1 reversed docetaxel resistance 
(7). By contrast, the expression of epithelial marker E-cadherin 
was downregulated in docetaxel-resistant cells (8). These results 
suggest docetaxel resistance in highly metastatic prostate cancer 
with a high level of epithelial–mesenchymal transition, support-
ing the superior anticancer effect of docetaxel chemotherapy for 
non-metastatic hormone-naïve prostate cancer compared with 
metastatic prostate cancer.
MeTASTATiC HORMOne-nAÏve 
PROSTATe CAnCeR
The results of the French GETUG-AFU-15 study were 
reported in 2013. It did not show any improvement of OS by 
combining docetaxel chemotherapy with ADT for metastatic 
hormone-naïve prostate cancer, although docetaxel chemo-
therapy did improve progression-free survival (PFS) (9). 
The results failed to overcome the traditional concept that 
ADT is only useful for metastatic hormone-naïve prostate 
cancer. However, in 2015, the CHAARTED study conducted 
by the Eastern Cooperative Oncology Group investigating 
the utility of up-front docetaxel chemotherapy for metastatic 
hormone-naïve prostate cancer showed improved PFS as well 
as OS (10). Furthermore, the STAMPEDE trial in the UK also 
reported that both PFS and OS were improved by docetaxel 
chemotherapy in addition to ADT (11). Thus, one study failed, 
but two others showed significant improvement with up-front 
docetaxel administration for metastatic hormone-naïve pros-
tate cancer, although all three studies were conducted with 
similar concept and design.
Why did those trials report controversial results? Although 
there seems to be several differences among those clinical trials, 
such as (i) the number of docetaxel cycles, (ii) sample size, (iii) 
proportion of high-volume disease, (iv) length of follow-up, 
and (v) unignorable chemotherapy-related mortality (12, 
13), we suggest that the most significant difference was the 
subsequent treatments after progression to CRPC. At the time 
when the GETUG-AFU-15 trial was conducted, most novel 
therapeutics against CRPC were under development. Then, 
only a few patients were treated with cabazitaxel and only a 
small number of patients were recruited to clinical trials using 
abiraterone acetate and enzalutamide (Table 1). In contrast, the 
CHAARTED and STAMPEDE trials were both conducted in 
era of novel therapeutics for CRPC. In the CHAARTED trial, 
cabazitaxel was utilized more frequently (24 vs. 13%) as were 
abiraterone acetate and enzalutamide (44 vs. 36%), in the ADT 
plus docetaxel group compared with the ADT monotherapy 
group, although docetaxel rechallenge was less frequent (23 vs. 
48%) (Table 1). Similarly, in the STAMPEDE trial, cabazitaxel 
was utilized more frequently (6 vs. 3%) as were abiraterone 
acetate and enzalutamide (35 vs. 30%) in the ADT plus doc-
etaxel group, although docetaxel rechallenge was less (14 vs. 
41%) (Table 1). Collectively, if there was no survival-prolonging 
agent, there may be no difference between up-front and delayed 
docetaxel use. However, now we can utilize several novel 
life-prolonging agents against CRPC, even in a postdocetaxel 
setting, which can be administered sequentially after up-front 
docetaxel chemotherapy. It has recently been reported that only 
4.4% of CRPC patients in the US received AR-targeting agents 
and cabazitaxel in addition to docetaxel chemotherapy (14); 
therefore, achieving sufficient use of therapeutics for CRPC 
would be difficult, which may compromise the merit of novel 
agents.
Up-front docetaxel chemotherapy is effective against 
hormone-naïve prostate cancer, as demonstrated by a recently 
published meta-analysis (13). Cabazitaxel chemotherapy is 
also active against prostate cancer, with evidence of improved 
OS among men with metastatic CRPC (15). The FIRSTANA 
study (NCT01308567) is now examining oncological 
outcome of docetaxel and cabazitaxel as first-line chemo-
therapy for metastatic CRPC. Therefore, up-front cabazitaxel 
TABLe 2 | Phase 3 clinical trials examining taxane chemotherapy for hormone-naïve prostate cancer.
Study identifier Organizer Taxane Stage Control arm Primary 
endpoint
Result
GETUG-AFU-15 NCT00104715 GETUG-AFU (French) Docetaxel Metastatic ADT OS, PFS Negative
CHAARTED NCT00309985 ECOG (US) Docetaxel Metastatic ADT OS Positive
STAMPEDE NCT00268476 Medical Research 
Council (UK)
Docetaxel Metastatic ADT OS Positive
SensiCab NCT01978873 Örebro University 
(Sweden)
Cabazitaxel Metastatic ADT OS NA
SPCG 12 NCT00376792 SPCG Docetaxel Non-metastatic RP (adjuvant) PFS NA
553 NCT00132301 Department of Veterans 
Affairs (US)
Docetaxel Non-metastatic RP (adjuvant) PFS NA
CALGB 90203 NCT00430183 CALGB (US) Docetaxel Non-metastatic RP with 
neoadjuvant ADT
PFS NA
XRP6976J 3501 NCT00283062 Sanofi Docetaxel Non-metastatic RP with adjuvant 
vs. salvage ADT
PFS Early terminated with 
negative result
RTOG-9902 NCT00004054 RTOG (US) Paclitaxel Non-metastatic RT with ADT OS Negative
GETUG 12 NCT00055731 GETUG (French) Docetaxel Non-metastatic RT (or RP) with 
adjuvant ADT
PFS Improved PFS
RTOG-0521 NCT00288080 RTOG (US) Docetaxel Non-metastatic RT with ADT OS Improved OS
SPCG 13 NCT00653848 SPCG Docetaxel Non-metastatic RT with ADT PFS NA
05-043 NCT00116142 Dana-Farber Cancer 
Institute (US)
Docetaxel Non-metastatic RT with ADT OS NA
DART NCT00651326 NCIC Clinical Trials 
Group (Canada)
Docetaxel Non-metastatic RT with ADT PFS NA
PEACE2 NCT01952223 Collaborative European 
Group
Cabazitaxel Non-metastatic Prostatic vs. pelvic 
RT with ADT
PFS NA
SPCG 14 – SPCG Docetaxel Non-metastatic, PSA 
recurrence after RP or RT
Bicalutamide PFS NA
RTOG-P-0014 NCT00030654 RTOG (US) Docetaxel Non-metastatic, PSA 
recurrence after RP or RT
Various OS NA
XRP6976J 3503 NCT00514917 Sanofi Docetaxel Non-metastatic, PSA 
recurrence after RP or RT
ADT PFS Early terminated with 
marginal result
OS, overall survival; PFS, progression-free survival; RP, radical prostatectomy; RT, radiotherapy.
TABLe 1 | Subsequent active therapy after progression to CRPC.
Study GeTUG-AFU-15 CHAARTeD STAMPeDe
Arm ADT plus docetaxel ADT ADT plus docetaxel ADT ADT plus docetaxel ADT
The number of enrolled cases, n 192 193 397 393 592 1184
The number of cases progressed to CRPC, n NA NA 238 287 311 750
Chemotherapy
Docetaxel 54 120 54 (23%) 137 (48%) 14% 41%
Cabazitaxel 3 2 57 (24%) 37 (13%) 6% 3%
AR-targeting agent
Abiraterone acetate 16a 29a 105 (44%) 104 (36%) 28% 23%
Enzalutamide 7% 7%
Orteronel NA NA NA NA
Others
Sipuleucel-T NA NA 22 (9%) 19 (5%) NA NA
Ra-223 NA NA NA NA 1% 0%
aReferred from Ref. (12).
NA, not available; percentage number represent the proportion among cases progressed to CRPC.
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chemotherapy combined with standard ADT can also be 
effective for metastatic hormone-naïve prostate cancer, which 
has been examined by the Swedish clinical trial SensiCab 
(NCT01978873, Table 2). A clinical trial comparing up-front 
docetaxel and cabazitaxel chemotherapy combined with ADT 
would be intriguing.
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nOn-MeTASTATiC HORMOne-nAÏve 
PROSTATe CAnCeR
In addition to the promising role of taxane chemotherapy for 
metastatic hormone-naïve prostate cancer, there may be the 
possibility of efficacy for non-metastatic hormone-naïve prostate 
cancer. This is supported by the basic research discussed above, 
as well as non-randomized clinical studies showing feasibility and 
modest efficacy. Accordingly, several phase 3 clinical studies have 
been under investigation (16).
Taxane Chemotherapy with Surgical 
Therapy
Radical prostatectomy for localized prostate cancer is the stand-
ard curative therapy and shows excellent oncological outcome. 
However, there is a high recurrence rate in high-risk patients, who 
are defined as high stage, high Gleason score, and high prostate-
specific antigen (PSA) level at diagnosis. To improve the outcome 
of high-risk localized prostate cancer, the Southwest Oncology 
Group explored the role of mitoxantrone chemotherapy after 
radical prostatectomy in oncological outcome in a phase 3 clinical 
trial of 983 patients (SWOG S9921, NCT00004124). They failed to 
show significant improvement of PFS as primary endpoint (17), 
although mitoxantrone was palliative but not life-prolonging for 
men with CRPC. However, because docetaxel has been shown to 
be active against prostate cancer, various studies using docetaxel 
chemotherapy have been conducted and are in progress (Table 2) 
(18). The Scandinavian Prostate Cancer Group (SPCG) group 
has been examining whether adjuvant docetaxel for high-risk 
prostate cancer after radical prostatectomy can improve outcome 
(SPCG 12, NCT00376792). A similarly designed phase 3 trial 
(NCT00132301) is also ongoing in the US. A phase 3 study by the 
Cancer and Leukemia Group B (CALGB 90203, NCT00430183) 
is comparing oncological outcome after radical prostatectomy 
with or without neoadjuvant docetaxel chemotherapy plus ADT 
in 750 randomized patients with high-risk prostate cancer. So far, 
only one study (XRP6976J_3501, NCT00283062) has been ter-
minated early because of poor recruitment of patients. The study 
was examining immediate treatment following prostatectomy vs. 
deferred treatment at the time of relapse with docetaxel plus ADT 
vs. ADT alone.
Taxane Chemotherapy with Radiotherapy
Similarly to surgical therapy, oncological outcome of radiotherapy 
for high-risk prostate cancer has been modest. Although combi-
nation with ADT can improve the outcome, the improvement is 
far from satisfactory, and further improvement has to be pursued. 
The Radiation Therapy Oncology Group (RTOG) has explored the 
role of chemotherapy with paclitaxel, estramustine, and etoposide 
combined with radiotherapy and long-term ADT in a phase 3 clini-
cal trial of 397 patients (RTOG-9902, NCT00004054). They failed 
to show significant improvement of OS as primary endpoint (19), 
although paclitaxel has never been shown to be active in prostate 
cancer treatment. Several clinical trials have examined the effect 
of active taxane chemotherapy, such as docetaxel and cabazitaxel, 
combined with radiotherapy as shown below and in Table 2. The 
GETUG 12 trial (NCT00055731) showed improved PSA decrease 
at 3 months, as well as improved relapse-free survival of neoad-
juvant docetaxel and estramustine chemotherapy, in addition to 
ADT plus local therapy, mostly with definitive radiotherapy for 
high-risk localized prostate cancer (20, 21). Consistently, RTOG 
(RTOG-0521, NCT00288080) has recently reported improved 
OS of docetaxel chemotherapy, in addition to ADT plus radio-
therapy (22). Thus, two randomized trials have recently shown 
superior prognosis with docetaxel chemotherapy combined with 
radiotherapy. In addition, The SPCG group has been investigating 
whether adjuvant docetaxel for high-risk prostate cancer after 
radiotherapy combined with ADT improves outcome (SPCG 13, 
NCT00653848) (23). They reported that toxicity in patients receiv-
ing adjuvant docetaxel was well tolerated although frequency 
of neutropenia was higher, but PFS as primary endpoint has 
not been reached. Similarly, they Dana-Farber Cancer Institute 
(NCT00116142) and a Canadian group (DART, NCT00651326) 
have been conducting phase 3 clinical trials examining whether 
docetaxel improves outcome after radiotherapy combined with 
ADT in patients with high-risk localized prostate cancer.
The novel taxane cabazitaxel is also under investigation. 
A European collaborative group has been conducting a 
phase 3 trial in patients with localized prostate cancer with 
high risk of relapse (PEACE2, NCT01952223), comparing 
ADT  +  prostate radiotherapy, ADT  +  pelvic radiotherapy, 
cabazitaxel  +  ADT  +  prostate radiotherapy, and cabazi-
taxel + ADT + pelvic radiotherapy.
Taxane Chemotherapy for non-Metastatic 
Recurrent Disease
For biochemical recurrent non-metastatic disease after radi-
cal prostatectomy or radiotherapy, ADT has been the primary 
standard therapeutic option. However, most recur in a castration-
resistant fashion, requiring improvement of management of such 
patients.
Accordingly, the SPCG group has been conducting a phase 
3 clinical trial (SPCG 14) to examine whether additional doc-
etaxel chemotherapy improves the outcome when combined 
with standard ADT. Similarly, the RTOG group has been 
conducting a phase 3 trial (RTOG-P-0014, NCT00030654) 
examining the effect of immediate vs. delayed docetaxel 
chemotherapy with ADT for PSA recurrence after definitive 
therapy. ADT with or without docetaxel for patients with rising 
PSA after radical prostatectomy was investigated in a phase 
3 trial (XRP6976J_3503, NCT00514917), but this study was 
terminated after all participants had completed treatment with 
docetaxel, showing marginal prolonged PFS by combining with 
docetaxel chemotherapy (19).
COnCLUSiOn
The battle between clonal selection and adaption theories in treat-
ment resistance is old, but it is a new debate in cancer biology. In 
favor of clonal selection theory, up-front docetaxel chemotherapy 
combined with ADT can almost eradicate androgen-dependent 
and CRPC cells, and result in prolonged cancer control. In contrast, 
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possibly more in favor of adaption theory, up-front docetaxel 
chemotherapy can exert a superior anticancer effect compared with 
when it is prescribed after obtaining castration resistance. Thus, 
although it remains unresolved, the success of the CHAARTED 
and STAMPEDE trials is a major advance in this field and indicates 
the superiority of up-front docetaxel chemotherapy.
Thus, up-front docetaxel could be an attractive option for 
selected patients. However, appropriate selection of patients for 
up-front chemotherapy would be important since monitoring the 
efficacy of up-front chemotherapy is almost impossible and toxic-
ity of chemotherapy cannot be ignored. It is important to identify 
patients who enjoy the benefit of up-front chemotherapy for meta-
static hormone-naïve prostate cancer and establish personalized 
medicine. These aims could be achieved by identifying predictors 
of poor response to hormonal therapy or good response to chemo-
therapy, using clinical characteristics or serum/genetic biomarkers.
Evidence that chemotherapy can improve the oncological out-
come of definitive therapy for non-metastatic prostate cancer has 
not been in the process of being obtained. Thus, efforts to extend 
the merit of up-front chemotherapy for metastatic hormone-
naïve prostate cancer by applying it to non-metastatic hormone-
naïve prostate cancer should be maintained. In addition, novel 
AR-targeting agents abiraterone acetate and enzalutamide have 
also been investigated in up-front application for metastatic 
hormone-naïve prostate cancer combined with conventional 
ADT, as well as non-metastatic hormone-naïve prostate cancer 
with definitive therapy. If those agents can improve prognosis, 
head-to-head comparison between up-front chemotherapy and 
up-front novel AR-targeting agents would be warranted in future, 
which could lead to major changes in prostate cancer therapy.
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